BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37952982)

  • 21. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
    Thépot S; Itzykson R; Seegers V; Recher C; Raffoux E; Quesnel B; Delaunay J; Cluzeau T; Marfaing Koka A; Stamatoullas A; Chaury MP; Dartigeas C; Cheze S; Banos A; Morel P; Plantier I; Taksin AL; Marolleau JP; Pautas C; Thomas X; Isnard F; Beve B; Chait Y; Guerci A; Vey N; Dreyfus F; Ades L; Ifrah N; Dombret H; Fenaux P; Gardin C;
    Am J Hematol; 2014 Apr; 89(4):410-6. PubMed ID: 24375487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
    Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
    Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.
    Wei AH; Roboz GJ; Dombret H; Dohner H; Schuh AC; Montesinos P; Selleslag D; Bondarenko SN; Prebet T; Lai Y; Skikne B; Beach CL; Ravandi F
    Haematologica; 2023 Oct; 108(10):2820-2825. PubMed ID: 36951156
    [No Abstract]   [Full Text] [Related]  

  • 26. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
    Craddock C; Jilani N; Siddique S; Yap C; Khan J; Nagra S; Ward J; Ferguson P; Hazlewood P; Buka R; Vyas P; Goodyear O; Tholouli E; Crawley C; Russell N; Byrne J; Malladi R; Snowden J; Dennis M
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):385-390. PubMed ID: 26363443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
    Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
    Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
    Gadaud N; Leroy H; Bérard E; Tavitian S; Leguay T; Dimicoli-Salazar S; Rieu JB; Luquet I; Largeaud L; Bidet A; Delabesse E; Klein E; Sarry A; de Grande AC; Bories P; Pigneux A; Récher C; Dumas PY; Bertoli S
    Leuk Lymphoma; 2022 Jun; 63(6):1398-1406. PubMed ID: 35634787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Falantes J; Pleyer L; Thépot S; Almeida AM; Maurillo L; Martínez-Robles V; Stauder R; Itzykson R; Pinto R; Venditti A; Bargay J; Burgstaller S; Martínez MP; Seegers V; Cortesão E; Foncillas MÁ; Gardin C; Montesinos P; Musto P; Fenaux P; Greil R; Sanz MA; Ramos F;
    Leuk Lymphoma; 2018 May; 59(5):1113-1120. PubMed ID: 28838276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
    Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
    Gaudy A; Laille E; Bailey R; Zhou S; Skikne B; Beach CL
    Clin Pharmacol Ther; 2023 Oct; 114(4):845-852. PubMed ID: 37422689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
    Vives S; Martínez-Cuadrón D; Bergua Burgues J; Algarra L; Tormo M; Martínez-Sánchez MP; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; López-Lorenzo JL; Gil C; Vidriales B; Falantes JF; Serrano A; Labrador J; Sayas MJ; Foncillas MÁ; Amador Barciela ML; Olave MT; Colorado M; Gascón A; Fernández MÁ; Simiele A; Pérez-Encinas MM; Rodríguez-Veiga R; García O; Martínez-López J; Barragán E; Paiva B; Sanz MÁ; Montesinos P;
    Cancer; 2021 Jun; 127(12):2003-2014. PubMed ID: 33626197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
    Wei AH; Döhner H; Sayar H; Ravandi F; Montesinos P; Dombret H; Selleslag D; Porkka K; Jang JH; Skikne B; Beach CL; Prebet T; Zhang G; Risueño A; Ugidos M; See WL; Menezes D; Roboz GJ
    Am J Hematol; 2023 Apr; 98(4):E84-E87. PubMed ID: 36655608
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
    Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
    Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
    Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
    Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.